Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

News & Analysis

China biotech company and industry news and analysis...

Week in Review: Hengrui and Dearon Announce $7.2 Billion in Drug Licensings

CStone Reports Positive Early Results from Phase I Trial of ROR1 ADC

Tyligand Starts US Trial of KRAS G12D Inhibitor for Solid Tumor Cancers

Degron Partners Molecular Glue Degraders with Takeda in $1.2 Billion Deal

Nona Bio Signs $604 Million License to Discover mAbs for AstraZeneca

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital